BRPI0517104A - tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico - Google Patents
tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmicoInfo
- Publication number
- BRPI0517104A BRPI0517104A BRPI0517104-0A BRPI0517104A BRPI0517104A BR PI0517104 A BRPI0517104 A BR PI0517104A BR PI0517104 A BRPI0517104 A BR PI0517104A BR PI0517104 A BRPI0517104 A BR PI0517104A
- Authority
- BR
- Brazil
- Prior art keywords
- kinase inhibitor
- bortezomib
- growth factor
- factor receptor
- receptor kinase
- Prior art date
Links
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 title abstract 4
- 229960001467 bortezomib Drugs 0.000 title abstract 4
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 3
- 102000001301 EGF receptor Human genes 0.000 title 1
- 108060006698 EGF receptor Proteins 0.000 title 1
- 238000011284 combination treatment Methods 0.000 title 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 229960001433 erlotinib Drugs 0.000 abstract 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 abstract 1
- -1 erlotinib HCI compound Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 229940120982 tarceva Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
TRATAMENTO COMBINADO COM BORTEZOMIB E UM INIBIDOR DE CINASE DE RECEPTOR DE FATOR DE CRESCIMENTO EPIDéRMICO. A presente invenção refere-se a um método para método de fabricação de um medicamento pretendido para tratar tumores ou metástases de tumor em um paciente, caracterizado pelo fato de que uma quantidade terapeuticamente eficaz de um inibidor de cinase de EGFR e bortezomib é usada, com ou sem agentes ou tratamentos adicionais, tal como outros fármacos anticâncer ou terapia de radiação. A invenção também abrange uma composição farmacêutica que é compreendida de um Inibidor de cinase de EGFR e combinação de bortezomib em uma combinação com um portador farmaceuticamente aceitável. Um exemplo preferido de um inibidor de cinase de EGFR que pode ser empregado na prática desta invenção é o composto HCI de erlotinib (também conhecido como Tarceva(r)).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61984404P | 2004-10-18 | 2004-10-18 | |
| PCT/US2005/037324 WO2006110175A2 (en) | 2004-10-18 | 2005-10-18 | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0517104A true BRPI0517104A (pt) | 2008-09-30 |
Family
ID=36922148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0517104-0A BRPI0517104A (pt) | 2004-10-18 | 2005-10-18 | tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060084691A1 (pt) |
| EP (1) | EP1804809A2 (pt) |
| JP (1) | JP2008516983A (pt) |
| KR (1) | KR20070083719A (pt) |
| CN (1) | CN101043892A (pt) |
| AU (1) | AU2005330507A1 (pt) |
| BR (1) | BRPI0517104A (pt) |
| CA (1) | CA2583520A1 (pt) |
| IL (1) | IL182584A0 (pt) |
| MX (1) | MX2007004549A (pt) |
| WO (1) | WO2006110175A2 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| CA2566971A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with irinotecan (cpt-11) and an egfr-inhibitor |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| US8404718B2 (en) * | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| WO2007146226A2 (en) * | 2006-06-09 | 2007-12-21 | Osi Pharmaceuticals, Inc. | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| US20070286864A1 (en) * | 2006-06-09 | 2007-12-13 | Buck Elizabeth A | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
| DK2076289T3 (da) | 2007-04-13 | 2015-02-09 | Dana Farber Cancer Inst Inc | Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider |
| WO2010022277A2 (en) * | 2008-08-20 | 2010-02-25 | O'connor Owen A | Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers |
| WO2010039762A2 (en) * | 2008-10-01 | 2010-04-08 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions comprising boronic acid compounds |
| CA2975473C (en) * | 2008-11-13 | 2021-01-19 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
| US9061037B2 (en) * | 2010-03-18 | 2015-06-23 | Innopharma, Inc. | Stable bortezomib formulations |
| EP2598114A1 (en) * | 2010-07-28 | 2013-06-05 | Fondazione Irccs "Istituto Nazionale del Tumori" | Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system. |
| CN103619337A (zh) * | 2011-05-16 | 2014-03-05 | 乌尔里克·努伯 | 新型癌症疗法和方法 |
| KR101695237B1 (ko) * | 2013-10-11 | 2017-01-12 | 이화여자대학교 산학협력단 | 보르테조밉을 유효성분으로 함유하는 간독성 질환의 예방 및 치료용 조성물 |
| EP3291819A4 (en) * | 2015-05-05 | 2018-11-21 | The Regents of the University of California | Improved drug combinations for drug-resistant and drug-sensitive multiple myeloma |
| WO2019169389A1 (en) * | 2018-03-02 | 2019-09-06 | Epicentrx, Inc. | Methods and compositions for treating cancer and sensitizing tumor cells to kinase inhibitors |
| BR112021006407A8 (pt) * | 2018-10-04 | 2022-12-06 | Inst Nat Sante Rech Med | uso de inibidores do egfr para ceratodermas |
| TW202237143A (zh) | 2020-12-10 | 2022-10-01 | 南韓商Ｌｇ化學股份有限公司 | 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物 |
| KR20220118247A (ko) | 2021-02-18 | 2022-08-25 | 김성운 | 커트용 헤어빗 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL146480A0 (en) * | 1999-05-14 | 2002-07-25 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| AU2003256847A1 (en) * | 2002-07-26 | 2004-02-16 | Advanced Research And Technology Institute At Indiana University | Method of treating cancer |
-
2005
- 2005-10-17 US US11/252,138 patent/US20060084691A1/en not_active Abandoned
- 2005-10-18 CA CA002583520A patent/CA2583520A1/en not_active Abandoned
- 2005-10-18 WO PCT/US2005/037324 patent/WO2006110175A2/en active Application Filing
- 2005-10-18 EP EP05857727A patent/EP1804809A2/en not_active Ceased
- 2005-10-18 JP JP2007537012A patent/JP2008516983A/ja active Pending
- 2005-10-18 MX MX2007004549A patent/MX2007004549A/es not_active Application Discontinuation
- 2005-10-18 AU AU2005330507A patent/AU2005330507A1/en not_active Abandoned
- 2005-10-18 BR BRPI0517104-0A patent/BRPI0517104A/pt not_active IP Right Cessation
- 2005-10-18 CN CNA200580035560XA patent/CN101043892A/zh active Pending
- 2005-10-18 KR KR1020077008837A patent/KR20070083719A/ko not_active Application Discontinuation
-
2007
- 2007-04-16 IL IL182584A patent/IL182584A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070083719A (ko) | 2007-08-24 |
| CN101043892A (zh) | 2007-09-26 |
| AU2005330507A1 (en) | 2006-10-19 |
| US20060084691A1 (en) | 2006-04-20 |
| EP1804809A2 (en) | 2007-07-11 |
| WO2006110175A3 (en) | 2007-03-08 |
| MX2007004549A (es) | 2007-07-11 |
| WO2006110175A2 (en) | 2006-10-19 |
| CA2583520A1 (en) | 2006-10-19 |
| JP2008516983A (ja) | 2008-05-22 |
| IL182584A0 (en) | 2008-04-13 |
| WO2006110175A9 (en) | 2006-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0517104A (pt) | tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico | |
| BRPI0510657A (pt) | tratamento com cisplatina e com um inibidor de egfr | |
| BRPI0511760A (pt) | tratamento com gemcitabina e um inibidor de egfr | |
| BRPI0511800A (pt) | tratamento com irinotecano (cpt-11) e um inibidor de egfr | |
| BRPI0517075A (pt) | uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer | |
| WO2007106503A3 (en) | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors | |
| WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| BR112014016163A8 (pt) | piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp | |
| BRPI0407834A (pt) | composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase | |
| WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
| BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
| HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
| MX2007009960A (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| TNSN07341A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| BRPI0417158A (pt) | composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença | |
| BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
| NZ598489A (en) | Combination therapy for treating proliferative diseases | |
| BRPI0610574A2 (pt) | uso de um inibidor de quinase para receptor do fator de crescimento epidérmico (egfr) em pacientes resistentes a gefitinib | |
| BRPI0511780A (pt) | tratamento com oxoliplatina e um inibidor de egrf | |
| JOP20200015A1 (ar) | توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين | |
| WO2009073139A3 (en) | Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit | |
| BRPI1008000A2 (pt) | composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto. | |
| CL2004000631A1 (es) | Compuestos derivados del acido 6-(2-bromofenil)-pirido[2,3-dipirimidin-7-carboxilico; composicion farmaceutica; procedimiento de preparacion; y uso para tratar el cancer y para preparar medicamentos para inhibir el crecimiento tumoral. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |